PubMed HealthSearch

Biomedical subjects

Arief Gusnanto

Publications and source records attributed to Arief Gusnanto.

2 recordsLinked to original sources

Sparse Logistic Regression on Genomic Data for Prediction of Tumour Pathological Subtype.

The correct prediction of tumour subtype is critical for the treatment of cancer patients to maximise the chance of survival. The patients' genomic information, such as copy number alterations (CNA) profile, has increasingly become an important factor in the prediction to supplement the traditional pathological subtyping. The incorporation of the CNA information in a prediction model, such as logistic regression, faces two major statistical challenges: first, how to estimate the model parameters in the thousands and, second, how to deal with the correlation of CNA between genomic regions. To address them, we propose a sparse logistic regression model with random effects where some of its parameters are estimated to zero while the other parameters are non-zero. In effect, a variable selection is embedded in the modelling. To deal with the correlation of CNA across genomic regions, we extend further the model to incorporate an additional penalty in the corresponding likelihood function in the logistic regression. The results show that we can identify selected genomic regions that are informative to distinguish different tumour subtypes, while giving a good prediction ability. We illustrate the methodology using CNA dataset from a lung cancer cohort.

Journal Article

GBMdeconvoluteR accurately infers proportions of neoplastic and immune cell populations from bulk glioblastoma transcriptomics data.

BACKGROUND: Characterizing and quantifying cell types within glioblastoma (GBM) tumors at scale will facilitate a better understanding of the association between the cellular landscape and tumor phenotypes or clinical correlates. We aimed to develop a tool that deconvolutes immune and neoplastic cells within the GBM tumor microenvironment from bulk RNA sequencing data. METHODS: We developed an IDH wild-type (IDHwt) GBM-specific single immune cell reference consisting of B cells, T-cells, NK-cells, microglia, tumor associated macrophages, monocytes, mast and DC cells. We used this alongside an existing neoplastic single cell-type reference for astrocyte-like, oligodendrocyte- and neuronal progenitor-like and mesenchymal GBM cancer cells to create both marker and gene signature matrix-based deconvolution tools. We applied single-cell resolution imaging mass cytometry (IMC) to ten IDHwt GBM samples, five paired primary and recurrent tumors, to determine which deconvolution approach performed best. RESULTS: Marker-based deconvolution using GBM-tissue specific markers was most accurate for both immune cells and cancer cells, so we packaged this approach as GBMdeconvoluteR. We applied GBMdeconvoluteR to bulk GBM RNAseq data from The Cancer Genome Atlas and recapitulated recent findings from multi-omics single cell studies with regards associations between mesenchymal GBM cancer cells and both lymphoid and myeloid cells. Furthermore, we expanded upon this to show that these associations are stronger in patients with worse prognosis. CONCLUSIONS: GBMdeconvoluteR accurately quantifies immune and neoplastic cell proportions in IDHwt GBM bulk RNA sequencing data and is accessible here: https://gbmdeconvoluter.leeds.ac.uk.

Humans